# Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

> **NCT00706342** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 18 (actual)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** Fostamatinib Disodium / R935788

## Key facts

- **NCT ID:** NCT00706342
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00706342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00706342, "Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00706342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*